Aurobindo Pharma incorporates wholly owned overseas subsidiary

M&A / JV 13 Aug 2026 · Announced· ✓ Verified

Aurobindo Pharma Limited, a Hyderabad-headquartered pharmaceutical major, filed a corporate governance notice with NSE intimating the incorporation of a wholly owned subsidiary. The precise acquisition target, consideration, and jurisdictional placement remain undisclosed in the subsidiary notice alone. This mechanism is typical for cross-border pharma M&A, where a special-purpose subsidiary is formed to hold or acquire assets abroad.

Why it mattersSubsidiary incorporation as acquisition SPV triggers subsidiary governance disclosures and potential foreign investment compliance under FEMA; monitor for follow-on announcement of target acquisition within 30–90 days.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals